scroll
for
more

your resources

Resources to further help you with BASAGLAR, including a video with a leading diabetes expert, clinical study reprints, tips for communicating with your Hispanic/Latino patients, and other information

key opinion leader

video

See what a diabetes expert says about BASAGLAR

BASAGLAR®

(insulin glargine injection) 100 units/mL

Clinical Reprints

Read published ELEMENT 1 (type 1 diabetes) and ELEMENT 2 (type 2 diabetes) clinical studies comparing BASAGLAR with Lantus® (insulin glargine injection) products (approved in the US or outside the US)

Blevins TC, Dahl D, Rosenstock J, et al. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab. 2015;17:726-733.

Rosenstock J, Hollander P, Bhargava A, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab. 2015;17:734-741.

tips for communicating with your

Hispanic/latino patients

The beginsulin™ experience also comes with resources tailored to the cultural needs of your Hispanic/Latino patients. Here are some insights and tips for your in-office discussions.

Basaglar®

(insulin glargine injection) 100 units/mL

A follow-on biologic to lantus

How a follow-on biologic gets approved in the US4

BASAGLAR is not considered a biosimilar in the US. It is considered a biosimilar in the European Union (EU) because it was approved under their biosimilar regulatory pathway.